Clinical Microbiology Newsletter
|
|
- Alberta Cameron
- 5 years ago
- Views:
Transcription
1 Clinical Microbiology Newsletter $88 Vol. 30, No May 15, 2008 Newer β-lactamases: Clinical and Laboratory Implications, Part I * Ellen Smith Moland, B.S.M.T., Soo-Young Kim, M.D., Seong Geun Hong, M.D., and Kenneth S. Thomson, Ph.D., Center for Research in Antiinfectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska Abstract For optimal patient care, clinical laboratories should be capable of detecting clinically significant, novel β-lactamases produced by gram-negative pathogens. However, with over 700 β-lactamases now described, it is a struggle to keep abreast of the various types of β-lactamases, their clinical relevance, and methods for detection. Furthermore, the increasing prevalence of isolates that produce multiple β-lactamases increases the difficulty of accurate detection. Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) recommendations for detection of β-lactamases do not keep pace with this rapidly evolving field. While perfection may not always be possible, it is important that clinical laboratories provide a relevant diagnostic service to ensure appropriate antibiotic therapy and infection control. Part I of this article will provide a brief discussion of extended-spectrum β-lactamases and methods for their laboratory detection. Introduction β-lactamases, the most important cause of bacterial resistance to β-lactam antibiotics, are enzymes that inactivate β-lactam antibiotics by hydrolysis of the β-lactam bond. These enzymes may differ in substrate profiles, i.e., the drugs they can inactivate. It is vital that clinical laboratories have the capability to detect clinically significant resistance caused by β-lactamases. Despite the discovery of extendedspectrum β-lactamases (ESBLs) in 1983 and plasmid-mediated AmpC β-lactamasesin 1989, asignificantnumber of *Editor s Note: Part II of this article will be published in the June 1, 2008 issue of CMN (Vol. 30, No. 11). Mailing Address: Ellen Smith Moland, B.S.M.T., Center for Research in Antiinfectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska Tel.: Fax: esmoland@creighton.eduand kstaac@creighton.edu clinical laboratories still have difficulty in detecting them and are unaware of the relevant reporting guidelines (1,2). There are also other novel β-lactamases, such as carbapenem-hydrolyzing enzymes and inhibitor-resistant variants of common β-lactamases. This article addresses the role of the clinical microbiology laboratory in detecting and reporting the newer β-lactamases. It also covers other issues, such as clinical significance, occurrence, and therapeutic considerations, regarding these resistance mechanisms. The primary focus of this article is to provide some helpful testing approaches that can be used in a variety of laboratory situations, including those where currently there are no Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) recommendations. These tests involve simple materials and a low to medium level of difficulty. Although they can be performed by individuals who have had little training, a microbiologist should interpret the test results. Extended-Spectrum Beta- Lactamases The term, extended-spectrum β-lactamase, refers to the distinctive substrate profile of these enzymes. Most are plasmid mediated: hydrolyze penicillins, cephalosporins, and aztreonam and are inhibited by β-lactamase inhibitors, such as clavulanate, tazobactam, and sulbactam. ESBLs cause clinically significant resistance to penicillins, cephalosporins, and aztreonam. ESBL-producing organisms occur worldwide with varying prevalences and types. They have been most commonly reported in isolates of Klebsiella spp. and Escherichia coli. They have also been reported in Enterobacter, Salmonella, Proteus, Citrobacter, Morganella morganii, Serratia marcescens, Clinical Microbiology Newsletter 30:10, Elsevier /00 (see frontmatter) 71
2 Shigella dysenteriae, Pseudomonas aeruginosa, Burkholderia cepacia, and Acinetobacter baumannii. It is important for clinical laboratorians to be aware that some ESBL-mediated resistance is not reliably detected by routinesusceptibility tests (3). If laboratories do not test appropriately, susceptibility reports may indicate false susceptibility to some β-lactam antibiotics and mislead clinicians into ineffectively treating infected patients. Carbapenems are the most effective antibiotics for treating infections caused by ESBL-producing Enterobacteriaceae (3).The CLSIreportingrecommendation for ESBL-producing isolates of Klebsiella spp., E. coli, andproteus mirabilis is to report resistance to all penicillins, cephalosporins, and aztreonam but to report cephamycin and β- lactamase inhibitor combinations tests without modification. The latter part of this recommendation is controversial, because cephamycin resistance due to altered porin expression may emerge (4-11) and piperacillin/tazobactam therapy has been reported to be less successful than carbapenem therapy (12-15). For this reason,some laboratories may choose either not to report cephamycins and β-lactamase inhibitor combinations or to report resistance to these agents. Carbapenems (e.g., imipenem, ertapenem, meropenem, and doripenem) are the most effective therapeutic agents for infections caused by ESBL-producing Enterobacteriaceae.SomeESBLproducing isolates may be susceptible in vitro to α-methoxy β-lactams, such as the cephamycins (e.g., cefoxitin and cefotetan) and moxalactam, as well as the aminoglycosides, fluoroquinolones, β-lactamase inhibitor combinations, or tigecycline; however, peer-reviewed therapeutic-outcome data are either lacking or less convincing than for the carbapenems. Classical ESBLs Classical ESBLs are ESBLs for which there is the most clinical experience in the United States and upon which the CLSI ESBL tests are predominantly based. Mutations in the common broadspectrum, plasmid-mediated β-lactamases TEM-1, TEM-2, and SHV-1 have expanded the hydrolytic spectrum of these enzymes (16). The parental enzymes (TEM-1, TEM-2, and SHV-1) hydrolyze penicillins and early cephalosporins, such as cephalothin, cefaclor, and cefazolin, but do not hydrolyze the later, more stable cephalosporins, like cefuroxime, cefixime, cefotaxime, ceftriaxone, ceftazidime, and cefepime, and the monobactam, aztreonam. The mutations extend the substrate profiles, permitting hydrolysis of at least some of the more stable drugs listed above. Currently, there are over 160 TEMand approximately 100 SHV-derived β-lactamases. Other ESBLs Other types of ESBLs may differ from TEM and SHV ESBLs with respect to detection and therapeutic issues (17). Some phenotypically resemble certain chromosomal β-lactamases, such as the K1 chromosomal β-lactamase of Klebsiella oxytoca and the chromosomal β-lactamases of Citrobacter koseri, Yersinia enterocolitica, Kluyvera spp., and Proteus vulgaris. Some, such as the CTX-M ESBLs, are derived from chromosomal enzymes and are not mutated forms of broadspectrum β-lactamases. The name derives from CTX, a common abbreviation for cefotaxime, which indicates the tendency of many CTX-M enzymes to hydrolyze cefotaxime faster than ceftazidime; however, a few CTX-Ms significantly hydrolyze ceftazidime (e.g., CTX-M-15, -19, -25, and -32). There are currently over 65 CTX-M ESBLs; some were previously designated Toho but now have CTX-M numbers ( are now the most common ESBLs worldwide. CTX-Ms have been detected mainly in isolates of Enterobacteriaceae, with E. coli being the predominant host. They have also been reported in isolates of P. aeruginosa and Stenotrophomonas maltophilia(18). Infectionscausedby community-acquired CTX-M ESBLproducing isolates are an increasing problem, and there have been many reports of clonally related outbreaks which have spread within the community and the hospital (19,20). Isolates that produce CTX-M ESBLS may have greatly reduced susceptibility to cefepime, with MICs of 64 μg/ml or higher (21).Thisisinsharpcontrasttothe majority of isolates that produce TEMand SHV-derived ESBLs. PER-1, -2, and -3 comprise a highly clavulanate-sensitive family of ESBLs, with a different epidemiology from the TEM and SHV ESBLs. PER-1, identified in 1991, has been detected in Enterobacteriaceae and nonfermenting gram-negative bacilli. PER-2 was first detected in Argentina and is now reported to be the second most prevalent ESBL in that country, having been found only in other SouthAmerican countries(22). PER-3 was discovered in an isolate of Aeromonas punctata (formerly Aeromonas caviae)infrance. ESBLs of the OXA family are increasing in occurrence. The OXA family of enzymes were given this name because they hydrolyze oxacillin and cloxacillin. These ESBLs occur mainly in P. aeruginosa. Ceftazidime resistance is a phenotypic marker, but the poor inhibition of OXAs by clavulanate can make ESBL phenotypic detection difficult. There are other individual nonclassical ESBLs that do not belong to the previously-mentioned families. These include VEB-, SFO-, and GES-type enzymes /00 (see frontmatter) 2008 Elsevier Clinical Microbiology Newsletter 30:10,2008
3 Detection of ESBLs in E. coli, Klebsiella, andp. mirabilis The two main approaches to ESBL detection are screening tests and specific (or confirmatory) tests. Screening tests detect reduced susceptibility to indicator drugs, such as cefotaxime, ceftriaxone, ceftazidime, cefpodoxime, aztreonam, and cefepime. The CLSI recommended indicator drugs are listed intable1(20).screeningtestsarenot specific because mechanisms other than ESBLs may also cause positive screens. Therefore, positive screens should be followed by confirmatory tests. If a laboratory does not test for all of the screening agents, the likelihood increases that screening tests will be less than 100% sensitive. Most ESBL confirmatory tests indirectly detect hydrolysis of indicator drugs, using the principles of the doubledisktest(23,24).thatis,esblproduction is confirmed if clavulanate significantly enhances the activity of the indicatordrug(fig. 1). Adiskcontaining clavulanate, usually amoxicillin/ clavulanate, is strategically placed on an inoculated Mueller-Hinton agar susceptibility plate, typically 30 mm or less from disks containing indicator drugs. The optimal disk spacing varies from strain to strain. Clavulanate-mediated enhancement of the activity of an indicator drug, seen as a lens of inhibition or a keyhole effect, is indicative of ESBL production. Interpretation of the confirmatory test is subjective, not quantitative. This test may present difficulties, because optimal disk spacing is not always achieved on initial testing and some results require considerable experience to interpret correctly. The CLSI ESBL confirmatory tests involve testing cefotaxime and ceftazidime alone and in combination with clavulanate(table2). Contrary toa common misunderstanding, the CLSI ESBL confirmatory disk tests are not the double disk test. The CLSI ESBL disktest(fig.2)involvesquantitative, as well as qualitative, interpretation, whereas the double-disk test is qualitative. The CLSI test is confirmatory if the inhibition zone of either cephalosporin increases at least 5 mm in the presence of clavulanate. The CLSI also recommends a dilutionmethodconfirmatory testing(table 2)by determiningmicsofceftazidime Table 1. CLSI ESBL screens for E. coli, Klebsiella, andp. mirabilis E. coli, Klebsiella pneumoniae, and Klebsiella oxytoca MIC test 2 μg/ml for cefotaxime, ceftriaxone, ceftazidime, or aztreonam and 8 μg/ml for cefpodoxime Disk test P. mirabilis MIC test Disk test Figure 1. Double-disk test showing keyhole positive results in tests with ceftazidime (CAZ), ceftriaxone (CRO), and cefotaxime (CTX), but not the cephamycin cefoxitin (FOX); the central disk is amoxicillin/clavulanate (AMC). and cefotaxime with and without the presence of clavulanic acid (4 μg/ml). A decrease in the MIC of either antimicrobial agent by 3 twofold dilutions in the presence of clavulanate is indicative of the presence of an ESBL. The Etest ESBL confirmatory test strips (AB Biodisk, Solna, Sweden) are based on the CLSI dilution method. One strip has concentration gradients of cefotaxime (0.25 to 16 μg/ml) and cefotaxime (0.016 to 1 μg/ml) plus 4 μg/ml clavulanic acid gradient, the other has a ceftazidime (0.5 to 32 μg/ml), and another strip has ceftazidime (0.064 to 17 mm for cefpodoxime, 22 mm for ceftazidime, 25 mm for ceftriaxone, and 27 mm for cefotaxime or aztreonam 2 μg/ml for cefpodoxime, cefotaxime, or ceftazidime 22 mm for cefpodoxime, 22 mm for ceftazidime, and 27 mm for cefotaxime Table 2. CLSI ESBL confirmatory tests for E. coli, Klebsiella, andp. mirabilis MIC test 3 two-fold concentration decrease in MIC of cefotaxime/ceftazidime +/- clavulanate 4 μg/ml Disk test 5-mm increase in zone diameter for cefotaxime/ceftazidime +/- clavulanate 10 μg CRO CAZ AMC FOX CTX 4 μg/ml) plus 4 μg/ml clavulanic acid gradients. These are less extensive concentration ranges than those recommended by CLSI, namely, cefotaxime (0.25 to 64 μg/ml) and ceftazidime (0.25 to 128 μg/ml) with and without 4 μg/ml of clavulanic acid. Consequently, the Etest strips may yield more nondeterminable, difficult-to-interpret results. The Etest method provides both quantitative and qualitative interpretations. The presence of an ESBL is confirmed by the appearance of a phantom zone or deformation of the cefotaxime or ceftazidime ellipse or when either Clinical Microbiology Newsletter 30:10, Elsevier /00 (see frontmatter) 73
4 the MIC of cefotaxime or ceftazidime is reduced by 3 log 2 dilutions in the presence of clavulanic acid. It should be noted that there is an additional cefepime-based Etest ESBL detection strip. This is discussed below. There are also automated systems, such as the Vitek Legacy and Vitek 2 (BioMérieux, Hazlewood, MO), Micro- Scan (Siemens Medical Solutions Diagnostics, Sacramento, CA), Sensititre (TREK Diagnostic Systems, Cleveland, OH), and Phoenix (BD Diagnostic Systems, Sparks, MD), that can detect ESBLs. These may involve ESBL screening and confirmatory tests, as well as expert system software to analyze susceptibility profiles that infer underlying resistance mechanisms. While helpful for many isolates, sometimes the expert systems provide misleading interpretations, because the software has not been sufficiently updated to cope with new ESBL typesofisolates (25,26). Regardlessofthe ESBL confirmatory methodology, some results may be inconclusive or non-determinable (beyond the limits of detection or offscale results). The laboratory must then use other confirmatory tests (if available) or report the results as inconclusive or non-determinable (with an explanation that ESBL production cannot be excluded). If an ESBL is detected in an isolate of Klebsiella spp., E. coli, orp. mirabilis, the CLSI recommends that the laboratory report resistance to all penicillins, cephalosporins, and aztreonam, regardless of thesusceptibilitytesting result(27). ThecurrentCLSI ESBL guidelines cover K. oxytoca, which produces the chromosomally encoded K1 β-lactamase. When hyperproduced, this enzyme may cause false-positive ESBL confirmatory tests. This enzyme is similar to ESBLs because it hydrolyzes cefpodoxime, ceftriaxone, and aztreonam efficiently but, unlike many ESBLs, does not usually hydrolyze ceftazidime. For therapeutic and infection control purposes, it is helpful to differentiate between ESBL production and hyperproduction of the K1 enzyme. Ceftazidime is, therefore, the most useful of the CLSI-recommended substrates for ESBL screening and confirmatory tests of K. oxytoca isolates. Positive CAZ/ CLA CAZ Figure 2. CLSI ESBL confirmatory disk test with ceftazidime (CAZ), alone and in combination with clavulanate (CAZ/CLA), and cefotaxime (CTX), alone and in combination with clavulanate (CTX/CLA). Although all four disks must be used, only one of the cephalosporin zones needs to be increased by at least 5 mm for a positive interpretation. Depending on the locations of the disks, it is also occasionally possible to get a keyhole result (double-disk test effect, as shown) to also indicate ESBL production. ceftazidime-basedtests are suggestive of ESBL production, and negative ceftazidime-based tests are suggestive of hyperproduction of the K1 enzyme. The value of this generalization is diminished in populations where CTX-M ESBLs are present in K. oxytoca isolates. As indicated above, CTX-M ESBLs may yield negative ceftazidime-based ESBL detection tests. If CTX-Ms are present, reduced susceptibility to cefepime may be a useful indicator for differentiating between K1 and CTX-M ESBLs in this organism. In 2005, P. mirabilis wasaddedto the list of organismsto screen foresbls (28).However, CLSI does not recommend routine screening of P. mirabilis for ESBL production, unless it is deemed clinically relevant, such as a bacteremic isolate. P. mirabilis is the second most common causative organism of urinary tract infections, so it is not clear why the CLSI has this recommendation only for serious infections. It would make sense to screen all P. mirabilis isolates, as they may harbor genes with ESBLs, which may later be transferred to other organisms and/or cause serious infections themselves. CTX/ CLA CTX ESBL Detection in Other Organisms ESBL-producing organisms other than E. coli, Klebsiella, or P. mirabilis also cause infections and may be unsuspected reservoirs of transferable multiple antibiotic resistance. Detection difficulties arise because there are no CLSI screening or confirmatory tests. An experienced microbiologist might be suspicious that a susceptibility pattern is suggestive of ESBL production in these organisms and should try one of the confirmatory tests mentioned previously. Even though it can be difficult to detect ESBLs, it is in the best interests of the patient and the hospital for the laboratory to attempt detection. Detection problems arise especially with organisms that produce an inducible AmpC β-lactamase, as clavulanate can induce high-level production of AmpC, which may obscure recognition ofanesbl(seeexampleintable3). One approach to circumvent this problem is to use cefepime, which is not significantly hydrolyzed by AmpC, as a substrate in clavulanate inhibitionbased ESBLtests(Fig. 3). Anotherapproachisto incorporate /00 (see frontmatter) 2008 Elsevier Clinical Microbiology Newsletter 30:10,2008
5 an inhibitor of AmpC β-lactamases, suchascloxacillin, intheagar(29a) and to utilize the CLSI-recommended disks (ceftazidime and cefotaxime, withandwithoutclavulanate)(fig.4). Thereis no CLSI recommendation to automatically report resistance to all penicillins, cephalosporins, and aztreonam if an ESBL is detected in organisms other than E. coli, Klebsiella, or P. mirabilis. According to the CLSI, susceptibility results should be reported without modification. This is inconsistent with the CLSI recommendation for ESBL-producing E. coli, Klebsiella, and P. mirabilis and implies that ESBLs are not clinically significant in organismsotherthan these.table4shows β-lactam MICs for an SHV-3-producing Citrobacter freundii isolate. According to current CLSI recommendations, a laboratory would report this isolate as susceptible to cefotaxime, ceftriaxone, and cefepime. We advocate extension of the CLSI reporting recommendations to cover all ESBL-producing organisms, i.e., report all ESBL-producing organisms as resistanttoallpenicillins,cephalosporins,and aztreonam(1).this is especially important with organisms that produce an inducible AmpC β- lactamase(table5),becausecefepime may be considered a therapeutic choice. AmpC Beta-lactamases Molecular classes of β-lactamases are based on the amino acid sequence and can be subdivided based on functional characteristics. Molecular class C, or AmpC, β-lactamases primarily hydrolyze the cephems (cephalosporins and cephamycins) but also hydrolyze penicillins and aztreonam. These enzymes are resistant to the currently available β-lactamase inhibitors clavulanate, sulbactam, and tazobactam. With rare exceptions, the hydrolysis of cephamycins, such as cefotetan and cefoxitin, is a property that can be helpfultodistinguishampcs fromesbls (16).The exceptions are the chromosomal AmpC of Hafnia alvei and imported Amp-C Class (ACC) enzymes which evolved from it. Genes encoding inducible chromosomal AmpC β-lactamases are part of the genomes of many gram-negative bacteria(table5).normally,ampcisproduced at a low level and does not cause resistance, but higher-level production of Figure 3. Example of an Etest investigational strip which has cefepime (PM) without and (PML) with clavulanate. The test is both quantitative and qualitative. This test can be quantitative, as the PM MIC is 2 μg/ml and the PML MIC is <0.064 μg/ml, which is >3 doubling dilutions. The zone between the cefepime and cefepime/clavulanate ellipses is referred to as a phantom zone. This provides a qualitative interpretation, in that the manufacturer recommends that isolates yielding a phantom zone be reported as ESBL positive. Table 3. Example of induction of AmpC interfering with CLSI ESBL confirmatory test Isolate Test agent MIC (μg/ml) SHV-2-producing Enterobacter cloacae Ceftazidime alone 4 Ceftazidime + 4 μg/ml clavulanate 16 Table 4. MICs in µg/ml: SHV-3-producing Citrobacter freundii Cefotaxime Ceftazidime Ceftriaxone Cefepime 2 μg/ml 32 μg/ml 4 μg/ml 0.5 μg/ml AmpC may cause resistance to the first-, second-, and third-generation cephalosporins, cephamycins, penicillins, and the β-lactamase inhibitor combinations. Higher-level AmpC production may occur as a consequence of mutation (derepression) or when the organism is exposed to an inducing agent. Cephamycins (e.g., cefoxitin and cefotetan), Cefepime Cefepime/clav ampicillin, and carbapenems are good inducers(table6).inductionistemporary and is reversed by removal of the inducing agent from the vicinity of the organism. Induction of AmpC is not of great clinical consequence, providing patients are not treated with two β-lactam antibiotics, one of which is an inducer and Clinical Microbiology Newsletter 30:10, Elsevier /00 (see frontmatter) 75
6 the other a substrate of AmpC. However, the selection of derepressed mutants can be a major concern. Mutants typically occur spontaneously at frequencies of about 1 in every 10 6 to 10 9 cells, are often present as subpopulations in infections, and may emerge to cause therapeutic failures, especially with secondand third-generation cephalosporins and aztreonam. There have been reports of resistance to these agents developing during treatment at rates from less than 20% to over 70%, depending on the site of infection(29b).becauseofthis,some laboratories automatically report resistance to the first-, second-, or thirdgeneration cephalosporins and aztreonam fortheorganismslistedintable5. Some β-lactam antibiotics that are poor inducers of AmpC tend to be good selectorsofmutants(table7). Susceptibility tests vary in reliability for detecting resistance in these organisms, but identification of the organisms listed intable5indicatesthe presenceof this resistance mechanism. Editor s Note: Part II of this article will be published in the June 1, 2008 issue of CMN (Vol. 30, No. 11). References 1. Livermore, D.M. et al Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J. Antimicrob. Chemother. 49: Tenover, F.C. et al Detection and reporting of organisms producing extended-spectrum ß-lactamases: survey of laboratories in Connecticut. J. Clin. Microbiol. 37: Paterson, D.L. and R.A. Bonomo Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18: Pangon, B. et al In vivo selection of a cephamycin resistant porin mutant of a CTX-1 ß-lactamase producing strain of Klebsiella pneumoniae. J. Infect. Dis. 159: Martinez-Martinez, L. et al In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expandedspectrum-cephalosporins. Antimicrob. Agents Chemother. 40: Ardanuy, C. et al. Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems. Antimicrob. Agents Chemother : Mueller-Hinton agar Table 5. Common organisms that produce inducible AmpC beta-lactamases Enterobacter spp. Citrobacter freundii Hafnia alvei Serratia marcescens Morganella morganii Providencia spp. Pseudomonas aeruginosa Aeromonas spp. Table 6. Inducer potentials of beta-lactam agents Good Variable Poor Cefoxitin Clavulanate Sulbactam Cefmetazole Desacetyl cefotaxime Tazobactam Imipenem Cefamandole Aztreonam Meropenem Cephalothin Third-generation cephalosporins Ampicillin Cefonicid Fourth-generation cephalosporins Table 7. Mutant selection Good selectors Second- and third-generation cephalosporins Aztreonam Mueller-Hinton agar with cloxacillin 200 µg/ml Figure 4. CLSI ESBL confirmatory disk test results for an E. coli isolate producing both an ESBL (CTX-M-14) and an AmpC β-lactamase (CMY-2). (Left) CLSI ESBL disks on Mueller- Hinton agar. (Right) Same disks on Mueller-Hinton agar supplemented with cloxacillin (200 μg/ml). The ESBL confirmation is only visible with cloxacillin-supplemented agar which has inhibited the AmpC produced by this isolate. Poor selectors Carbapenems Cephamycins First- and fourth-generation cephalosporins Penicillins 7. Hernandez-Alles, S. et al Development of resistance during antimicrobial therapy caused by insertion sequence interruption of porin genes. Antimicrob. Agents Chemother. 43: Crowley, B., V.J. Benedi, and A. Domenech-Sanchez Expression of SHV-2 beta-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob. Agents Chemother. 46: Nelson, E.C., H. Segal, and B.G. Elisha Outer membrane protein alterations and blatem-1 variants: their role in {beta}-lactam resistance in Klebsiella pneumoniae. J. Antimicrob. Chemother. 52: Skopkova-Zarnayova, M. et al Outer membrane protein profiles of clonally related Klebsiella pneumoniae /00 (see frontmatter) 2008 Elsevier Clinical Microbiology Newsletter 30:10,2008
7 isolates that differ in cefoxitin resistance. FEMS Microbiol. Lett. 243: Lee, C.H. et al In vivo selection of OmpK35-deficient mutant after cefuroxime therapy for primary liver abscess caused by Klebsiella pneumoniae. J. Antimicrob. Chemother. 58: Burgess, D.S. et al Clinical and microbiologic analysis of a hospital s extended-spectrum beta-lactamaseproducing isolates over a 2-year period. Pharmacotherapy 23: Paterson, D.L. et al Fatal infection due to extended-spectrum betalactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. Clin. Infect. Dis. 28: Pillay, T. et al Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am. J. Perinatol. 15: Karadenizli, A. et al Piperacillin with and without tazobactam against extended-spectrum beta-lactamaseproducing Pseudomonas aeruginosa in a rat thigh abscess model. Chemotherapy 47: Bush, K., G.A. Jacoby, and A.A. Medeiros A functional classification scheme for ß-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39: Thomson, K.S. and E. Smith Moland Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect. 2: al Naiemi, N., B. Duim, and A. Bart A CTX-M extended-spectrum beta-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J. Med. Microbiol. 55: Lewis, J.S., II et al First report of the emergence of CTX-M-type extendedspectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob. Agents Chemother. 51: Moubareck, C. et al Countrywide spread of community- and hospitalacquired extended-spectrum betalactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J. Clin. Microbiol. 43: Moland, E.S. et al Discovery of CTX-M-like extended-spectrum betalactamases in Escherichia coli isolates from five U.S. States. Antimicrob. Agents Chemother. 47: Power, P. et al Biochemical characterization of PER-2 and genetic environment of blaper-2. Antimicrob. Agents Chemother. 51: Brun-Buisson, C. et al Transferable enzymatic resistance to thirdgeneration cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet ii: Jarlier, V. et al Extended broadspectrum ß-lactamases conferring transferable resistance to newer ß-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10: Espedido, B.A., L.C. Thomas, and J.R. Iredell Metallo-beta-lactamase or extended-spectrum beta-lactamase: a wolf in sheep s clothing. J. Clin. Microbiol. 45: Thomson, K.S. et al Comparison of Phoenix and VITEK 2 extendedspectrum-beta-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized beta-lactamases. J. Clin. Microbiol. 45: Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 17th informational supplement M100- S17. Clinical and Laboratory Standards Institute, Wayne, PA. 28. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; 15th informational supplement M100- S15. Clinical and Laboratory Standards Institute, Wayne, PA. 29a. Poirel, L. et al Outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J. Clin. Microbiol. 41: b. Sanders Jr., W.E. and C.C. Sanders Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin. Microbiol. Rev. 10: Clinical Microbiology Newsletter 30:10, Elsevier /00 (see frontmatter) 77
Expert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationJOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1998, p Vol. 36, No. 9. Copyright 1998, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 1998, p. 2575 2579 Vol. 36, No. 9 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Can Results Obtained with Commercially
More informationJournal of Infectious Diseases and
Journal of Infectious Diseases & Therapy ISSN: 2332-0877 Journal of Infectious Diseases and Therapy Santanirand et al., J Infect Dis Ther 2018, 6:5 DOI: 10.4172/2332-0877.1000378 Research Article Open
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationReceived 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationDisclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program
47 th Annual Meeting August 2-4, 2013 Orlando, FL Extended Spectrum β Lactamases: The New Normal Disclosure I do have a vested interest in or affiliation with the following companies or organizations Triax
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationEVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS
Indian Journal of Medical Microbiology, (2005) 23 (2):120-124 Brief Communication EVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS S Singhal, T
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationNew Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection
New Mechanisms of Antimicrobial Resistance and Methods for Carbapenemase Detection Stephen G. Jenkins, PhD, F(AAM), D(ABMM) Professor of Pathology and Laboratory Medicine Professor of Pathology in Medicine
More informationExtended-Spectrum -Lactamases: a Clinical Update
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2005, p. 657 686 Vol. 18, No. 4 0893-8512/05/$08.00 0 doi:10.1128/cmr.18.4.657 686.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Extended-Spectrum
More informationClinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes
56 Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended- Spectrum β-lactamase and AmpC Enzymes Patrick N. A. Harris, BSc, MBBS, MRCP, DTM&H, FRACP, FRCPA 1 1 Infection and
More informationAMPC BETA LACTAMASES AMONG GRAM NEGATIVE CLINICAL ISOLATES FROM A TERTIARY HOSPITAL, SOUTH INDIA. Mohamudha Parveen R., Harish B.N., Parija S.C.
Brazilian Journal of Microbiology (2010) 41: 596-602 ISSN 1517-8382 AMPC BETA LACTAMASES AMONG GRAM NEGATIVE CLINICAL ISOLATES FROM A TERTIARY HOSPITAL, SOUTH INDIA Mohamudha Parveen R., Harish B.N., Parija
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationReceived 21 September 1999/Returned for modification 26 November 1999/Accepted 18 February 2000
JOURNAL OF CLINICAL MICROBIOLOGY, May 2000, p. 1791 1796 Vol. 38, No. 5 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Occurrence and Detection of AmpC Beta-Lactamases
More informationCARBAPENEMASE PRODUCING ENTEROBACTERIACEAE
CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE Veroniek Saegeman Veroniek Saegeman UZLeuven Carbapenemase producing Enterobacteriaceae (CPE) Introduction on antibiotic resistance Classification of ß-lactamases
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationbreakpoints, cephalosporins, CLSI, Enterobacteriacae, EUCAST, review Clin Microbiol Infect 2008; 14 (Suppl. 1):
REVIEW Breakpoints for intravenously used cephalosporins in Enterobacteriaceae EUCAST and CLSI breakpoints G. Kahlmeter Department of Clinical Microbiology, Central Hospital, Växjö, Sweden ABSTRACT It
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationCOMMENTARY. Extended-Spectrum- -Lactamase, AmpC, and Carbapenemase Issues. Kenneth S. Thomson*
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2010, p. 1019 1025 Vol. 48, No. 4 0095-1137/10/$12.00 doi:10.1128/jcm.00219-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. COMMENTARY
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationKlebsiella pneumoniae 21 PCR
2011 11 TEM-132 ESBL Klebsiella pneumoniae 1) 2) 1) 1) 3) 2) 1) 2) 3) 19 6 27 22 10 20 2003 4 2004 11 95 ceftazidime (CAZ) Klebsiella pneumoniae 21 PCR b- (ESBL) PCR (PFGE) PCR bla TEM-132 PFGE 19 TEM-132
More informationCarbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan
Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan An Infection Control Emergency Speaker: L Kristopher Siu Principal Investigator Division of Infectious Diseases National Institute
More informationChapter 2. Detection of ESBL producing Enterobacteriaceae
Chapter 2 Detection of ESBL producing Enterobacteriaceae Chapter 1 22 Chapter 2.1 Laboratory detection of extended-spectrum β-lactamase-producing Enterobacteriaceae: evaluation of two screening agar plates
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationCAT Critically Appraised Topic
CAT Critically Appraised Topic Part I: Evaluation of Three Different Agar Media for Rapid Detection of Extended- Spectrum β-lactamase Producing Enterobacteriaceae from Clinical Screening Samples. Part
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMolecular characterisation of CTX-M-type extendedspectrum β-lactamases of Escherichia coli isolated from a Portuguese University Hospital
EJHP Science Volume 17 2011 Issue 3 P. 1-5 2011 Pharma Publishing and Media Europe. All rights reserved 1781-7595 25 www.ejhp.eu Molecular characterisation of CTX-M-type extendedspectrum β-lactamases of
More informationA new diagnostic microarray (Check-KPC ESBL) for detection and. identification of extended-spectrum beta-lactamases in highly resistant
JCM Accepts, published online ahead of print on 8 June 2011 J. Clin. Microbiol. doi:10.1128/jcm.02087-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationThis material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.
Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted
More information(DHA-1): Microbiologic and Clinical Implications
AAC Accepts, published online ahead of print on 20 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00083-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationORIGINAL INVESTIGATION. Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City
ORIGINAL INVESTIGATION Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City A New Threat to Our Antibiotic Armamentarium Simona Bratu, MD; David Landman, MD; Robin Haag, RN; Rose
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationORIGINAL ARTICLE. Julie Creighton and Clare Tibbs. Canterbury Health Laboratories, Christchurch
ORIGINAL ARTICLE Evaluation of the MAST indirect carbapenemase test and comparison with a modified carbapenem inactivation method for the detection of carbapenemase enzymes in Gram-negative bacteria Julie
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationEUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator
EUCAST Frequently Asked Questions Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator Erika Matuschek EUCAST Development Laboratory, Växjö Sweden Monday 24
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationThe b-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter
Review TRENDS in Microbiology Vol.14 No.9 The b-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter David M. Livermore and Neil Woodford Antibiotic Resistance Monitoring and Reference
More informationTranslocation Studies Mid-Term Review (MTR) Meeting Marseille, France
Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier Background Deteriorating situation regarding
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationCephalosporin MIC Distribution of Extended-Spectrum- -Lactamaseand pampc-producing Escherichia coli and Klebsiella Species
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2009, p. 2419 2425 Vol. 47, No. 8 0095-1137/09/$08.00 0 doi:10.1128/jcm.00508-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Cephalosporin
More informationComparative Activity of Cefotaxime and Selected f3-lactam Antibiotics Against Haemophilus Influenzae and Aerobic Gram-Negative Bacilli
REVIEWS OF INFECTIOUS DISEASES VOL. 4, SUPPLEMENT SEPTEMBER-OCTOBER 1982 1982 by The University of Chicago. All rights reserved. 0162-0886/82/0405-0015$02.00 Comparative Activity of Cefotaxime and Selected
More informationRapid identification of emerging resistance in Gram negatives. Prof. Patrice Nordmann
Rapid identification of emerging resistance in Gram negatives Prof. Patrice Nordmann Emerging Resistance threats, CDC USA-2013 Enterobacteriaceae producing extendedspectrum β-lactamases (ESBL) Multi-resistant
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary
More informationPerformance of chromid ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum b-lactamases
Journal of Medical Microbiology (2008), 57, 310 315 DOI 10.1099/jmm.0.47625-0 Performance of chromid ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum b-lactamases
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationSUPPLEMENTAL TESTING. Tan Thean Yen
SUPPLEMETAL TESTG Tan Thean Yen To Supplement Definition: add as a supplement to what seems insufficient "supplement your diet" Why supplement? urrent methods don t work well Additional information provided
More informationInsert for Kit 98006/98010/ KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J
Insert for Kit 98006/98010/98015 KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J DATE OF ISSUE: 09.02.2017 LANGUAGE: English FOR IN VITRO DIAGNOSTIC
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationIn Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria
In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria Warunee Punpanich MD*, Worraporn Tantichattanon MD**, Siriporn Wongwatcharapaiboon MD**, Vipa Treeratweeraphong BSc, MSc***
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationCefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
Fukuchi et al. BMC Infectious Diseases (2016) 16:427 DOI 10.1186/s12879-016-1770-1 RESEARCH ARTICLE Open Access Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
More informationResults and experience of BARN ESBL project. Marina Ivanova and project team Tallinn
Results and experience of BARN ESBL project Marina Ivanova and project team Tallinn 13.05.2013 Aim of the project Improvement of detection and surveillance of resistance caused by extended spectrum betalactamase
More informationjmb Research Article Review Semi Kim 1, Ji Youn Sung 2, Hye Hyun Cho 3, Kye Chul Kwon 1, and Sun Hoe Koo 1 *
J. Microbiol. Biotechnol. (2014), 24(6), 765 770 http://dx.doi.org/10.4014/jmb.1306.06036 Review Research Article jmb Characterization of CTX-M-14- and CTX-M-15-Producing Escherichia coli and Klebsiella
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationDetection of Carbapenem Resistant Enterobacteriacae from Clinical Isolates
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 5 (2016) pp. 864-869 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.505.089
More informationClinical significance of extended-spectrum
Clinical significance of extended-spectrum β-lactamases Expert Rev. Anti Infect. Ther. 6(5), 671 683 (2008) Jesús Rodríguez-Baño and Alvaro Pascual Author for correspondence Sección de Enfermedades Infecciosas,
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More information#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01754-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Title: Escherichia
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationInt.J.Curr.Microbiol.App.Sci (2016) 5(1):
ISSN: 2319-7706 Volume 5 Number 1(2016) pp. 200-208 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.501.018 Incidence of Beta Lactamases Mediated
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationAbstract. Introduction. Editor: R. Canton
ORIGINAL ARTICLE BACTERIOLOGY A simple, robust and rapid approach to detect carbapenemases in Gram-negative isolates by MALDI-TOF mass spectrometry: validation with triple quadripole tandem mass spectrometry,
More informationNature and Science 2017;15(10)
Evaluation of Substrate Profile Test for Detection of Metallobetalactamses among Imipenem Resistant Clinical Isolates of Gram Negative Bacteria Tarek El-said El-Banna, Fatma Ibrahim Sonboland Eslam Shaaban
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationDetecting carbapenemases in Enterobacteriaceae
Detecting carbapenemases in Enterobacteriaceae David Livermore Health Protection Agency, Colindale, London 12 August 2003 Mechanisms of carbapenem R in Enterobacteria Impermeability + AmpC or ESBL Metallo
More informationResistance to Polymyxins in France
Resistance to Polymyxins in France Paris Prof. Patrice Nordmann NDM producers in Enterobacteriaceae The polymyxins; colistin and polymyxin B Colistin - Synthesis by Bacillus polymyxa spp colistinus -
More informationDistribution of TEM, SHV and CTX-M Genes among ESBL-producing Enterobacteriaceae isolates in Iran
African Journal of Microbiology Research Vol. 6(26), pp. 5433-5439, 12 July, 2012 Available online at http://www.academicjournals.org/ajmr DOI: 10.5897/AJMR11.017 ISSN 1996-0808 2012 Academic Journals
More informationAuthor: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents
t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationDevelopment of a phenotypic method for fecal carriage detection of OXA-48-producing
JCM Accepts, published online ahead of print on 11 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00055-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationCephalosporin, Against Cephalosporin-Resistant Bacteria, and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1979, P. 59-553 Vol. 16, No. 5 66-/79/11-59/$2./ Antibacterial Activity of Ceftizoxime (FK 79), a New Cephalosporin, Against Cephalosporin-Resistant Bacteria,
More informationPrevalence of ESBL producing enterobacteriaceae in diabetic foot ulcers
Original Research Article Prevalence of ESBL producing enterobacteriaceae in diabetic foot ulcers Anitha S 1*, Natarajan V 2 1 Post Graduate, 2 Professor and HOD Department of Microbiology, Rajah Muthiah
More informationDetection of the KPC-2 Carbapenem-Hydrolyzing Enzyme in Clinical Isolates of ACCEPTED
JCM Accepts, published online ahead of print on April 00 J. Clin. Microbiol. doi:./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationCarbapenemases: the Versatile -Lactamases
CLINICAL MICROBIOLOGY REVIEWS, July 2007, p. 440 458 Vol. 20, No. 3 0893-8512/07/$08.00 0 doi:10.1128/cmr.00001-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Carbapenemases:
More informationAmpC -Lactamases. George A. Jacoby* Lahey Clinic, Burlington, Massachusetts
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2009, p. 161 182 Vol. 22, No. 1 0893-8512/09/$08.00 0 doi:10.1128/cmr.00036-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. AmpC -Lactamases
More information